The neuroprotection biotech also strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist, to the Scientific Advisory Board
The ongoing phase 1 clinical trial of its neuroprotective and remyelinating compound BN201 is due for completion early 2019
Barcelona, Spain, October 9, 2018 - Bionure Farma, a biotech company specialized in neuroprotection, today announces the appointment of Dr. Laurent Nguyen as the new Chief Executive Officer of the company and names Dr. Amit Bar-Or as member of its Scientific Advisory Board (SAB) led by Dr. Pablo Villoslada, the scientific founder of the company.
The Chairman of Bionure, Guy P. Nohra said “After a comprehensive search, the Board of Directors is very pleased to have attracted Dr. Nguyen, an accomplished executive, to assume leadership of Bionure, and to welcome Dr. Bar-Or to the SAB of the company as we are approaching the very exciting translational phase toward clinical proof-of-concept in patients with neurodegenerative diseases.”
Dr. Laurent Nguyen, a French national, graduated as Doctor of Medicine and holds a Master’s Degree in Public Health. Following a four-year residency at the Paris Hospital Group (Assistance Publique – Hopitaux de Paris), he built solid experience in the pharmaceutical industry at Hoechst-Roussel, Merck KGaA, F. Hoffmann-La Roche Ltd and Pierre Fabre. He then moved to the biotech sector where he became CEO of a French academic spin-off that he developed into a publicly traded clinical biotech company. He reached phase 2 clinical trials with a portfolio of neuro-otology (inner ear disorders) products. He also acted as advisor in corporate development for several biotech and medtech companies.
"I'm excited about the Bionure project, which is a potential game-changer for patients living with neurodegenerative diseases. I’m eager to join the great team that has taken the project forward into clinical development," said Dr. Nguyen.
Bionure is also expanding its Scientific Advisory Board with the appointment of Dr. Amit Bar-Or, Director of the Center for Neuroinflammation and Experimental Therapeutics, Chief of the Multiple Sclerosis Center at the University of Pennsylvania Perelman School of Medicine (Philadelphia, USA) and President of the International Society of Neuroimmunology. Dr. Bar-Or trained at McGill Medical School in Montreal, the Massachusetts General Hospital and the Harvard Center for Neurological Diseases. He focuses his research on the roles of functionally distinct immune cell subsets in autoimmune disease and immune-CNS interactions. His clinical work is centered on multiple sclerosis and related conditions, in both children and adults.
Bionure’s lead compound, BN201, is a small molecule currently in clinical phase 1 study in the UK, with results expected at the beginning of 2019.
BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases
The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new CMO
Barcelona, Spain, May 16, 2018. Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces today the initiation of a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom.
BN201 is a first-in-class compound that promotes cell survival and endogenous natural repair by activating SKG2, an intracellular serine/threonine kinase that plays a crucial role in the response of neurons to stress and its survival. The Phase 1 clinical trial is intended to investigate safety, tolerability and pharmacokinetics of single and multiple doses of BN201 in healthy volunteers. Results are expected by the end of the year and the company’s plan is to start a Phase 2a trial in 2019. (...)
MENLO PARK, CA. January 09, 2015. Bionure, Inc. a California-based late-preclinical drug development company, today announced that it has entered into a Sponsored Research Agreement with the National Multiple Sclerosis Society through Fast Forward, its commercial research subsidiary aimed at accelerating the development of new and improved therapies for MS. Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in Acute Optic Neuritis (AON). Optic neuritis is often a first sign of multiple sclerosis.
PALO ALTO, CA. May 27, 2014. Bionure Inc. today announced its drug candidate, BN201, was shown to promote myelination — the cellular process of repairing the protective sheath surrounding nerves that is damaged in people with multiple sclerosis (MS). The pre‐clinical study was conducted in a novel cell culture assay developed by the Myelin Repair Foundation (MRF) and assessed at the Foundation’s Translational Medicine Center under a previously announced collaborative agreement.
SARATOGA, CA. October 31, 2013. The Myelin Repair Foundation (MRF) and Bionure, Inc. today entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis (MS). The Foundation’s unique Accelerated Research Collaboration™ (ARC™) model facilitates collaboration between the top MS leaders worldwide to advance promising compounds into the clinic. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company’s proprietary MS therapeutic compound, BN201.